最新數據揭示了司美格魯肽對肥胖相關健康疾病的益處
New data reveals semaglutide's benefits for obesity-related health conditions
Updated at: June 7, 2026 at 10:45 AM
近期的臨床研究正在改變我們對司美格魯肽的看法。
Recent clinical research is changing how we view semaglutide.
長期以來，它主要被視為一種減重工具，但最新數據證實，這種GLP-1受體激動劑能為肥胖相關的健康狀況提供廣泛的保護。
Long considered primarily a weight-loss tool, new data confirms that this GLP-1 receptor agonist offers broad protection against obesity-related health conditions.
具有里程碑意義的研究，如SELECT試驗，顯示每週注射一次司美格魯肽能顯著降低心臟病發作和中風的風險。
Landmark studies, such as the SELECT trial, show that weekly semaglutide significantly reduces the risk of heart attacks and strokes.
除了心臟健康外，司美格魯肽在管理脂肪肝疾病以及保護肥胖和糖尿病患者的腎功能方面也展現出前景。
Beyond heart health, semaglutide shows promise in managing fatty liver disease and preserving kidney function in patients with obesity and diabetes.
儘管會出現噁心等常見的胃腸道副作用，但該藥物的治療潛力正在不斷擴大。
While common gastrointestinal side effects like nausea occur, the drug's therapeutic potential is expanding.
研究人員目前正在調查它對從多囊卵巢綜合症(PCOS)到成癮等各種疾病的影響。
Researchers are currently investigating its impact on conditions ranging from PCOS to addiction.
這種認知的轉變標誌著一個重要的醫學里程碑：司美格魯肽正在從一種單純的體重管理藥物演變為一種綜合性的代謝和心血管治療藥物。
This shift in understanding marks a significant medical milestone: semaglutide is evolving from a simple weight-management drug into a comprehensive metabolic and cardiovascular therapeutic.
重點不再僅僅是體重計上的數字，而是減輕與肥胖相關的全身性風險。
It is no longer just about the number on the scale; it is about mitigating the systemic risks associated with obesity.
與任何治療一樣，它必須在醫療監督下使用，且最好結合健康的飲食和持續的體育鍛鍊。
As with any treatment, it must be used under medical supervision, ideally combined with a healthy diet and consistent physical exercise.
